These activated DCs and pro-inflammatory Mfs have a central role in IBD, perpetuating disease activity independently of the adaptive immune inflammatory mechanisms targeted by anti-TNFα therapy (6). This evidence concerns the gene TNF and inflammatory bowel disease.